Table 2 Overview of current clinical trials targeting inflammation in cancer
From: Role of inflammasomes in cancer immunity: mechanisms and therapeutic potential
Agent | Target | Clinical trial | Drug regimen | Disease and number of participants (n) | Phase |
|---|---|---|---|---|---|
Anakinra | IL-1 receptor | NCT04099901 | Monotherapy | Multiple myeloma (90) | II |
| Â | Â | NCT03430011 | Combination with JCARH125 | Multiple myeloma (245) | I/II |
| Â | Â | NCT04205838 | Combination with CAR T cell therapy | Diffuse large B cell lymphoma (36) | II |
| Â | Â | NCT04148430 | Combination with CAR T cell therapy | B cell acute lymphoblastic leukaemia, B cell lymphoma, B cell non-Hodgkin lymphoma (90) | II |
Canakinumab | IL-1β | NCT04239157 | Combination with anacitidine | Myelodysplastic syndrome or chronic myelomonocytic leukaemia (60) | II |
Isunakinra | IL-1 receptor | NCT04121442 | Combination with a PD-(L)1 inhibitor | Solid tumours (25) | I/II |
Infliximab | TNF-α | NCT04407247 | Combination with vedolizumab | Genitourinary cancer or melanoma (100) | I/II |
Infliximab/Certolizumab | TNF-α | NCT03293784 | Combination with nivolumab and ipilimumab | Melanoma (30) | I |
Tocilizumab | IL-6 receptor | NCT03135171 | Combination with trastuzumab and pertuzumab | Breast cancer (20) | I |
| Â | Â | NCT04258150 | Combination with ipilimumab, nivolumab, and radiotherapy | Pancreatic cancer (30) | II |
| Â | Â | NCT02767557 | Combination with gemcitabine | Unresectable pancreatic carcinoma (140) | II |
| Â | Â | NCT04524871 | Combination with atezolizumab and bevacizumab | Advanced-stage liver cancers (100) | I/II |
| Â | Â | NCT04338685 | Combination with RO7119929 | Liver cancer (100) | I |
| Â | Â | NCT03821246 | Combination with atezolizumab | Prostate adenocarcinoma (34) | II |
| Â | Â | NCT04554771 | Combination with paclitaxel, carboplatin, and radiotherapy | Oesophageal adenocarcinoma (48) | II |
| Â | Â | NCT03970226 | Monotherapy | Adamantinomatous craniopharyngioma (27) | I |
| Â | Â | NCT03999749 | Combination with ipilimumab and nivolumab | Melanoma (67) | II |
Siltuximab | IL-6 | NCT04191421 | Combination with spartalizumab | Metastatic pancreatic adenocarcinoma (42) | I, II |
Galunisertib | TGF-β receptor | NCT02452008 | Combination with enzalutamide | Prostate cancer (60) | II |
| Â | Â | NCT02672475 | Combination with paclitaxel | Metastatic androgen receptor-negative triple-negative breast cancer (29) | I |
| Â | Â | NCT02688712 | Combination with capecitabine and fluorouracil | Rectal adenocarcinoma (50) | II |
| Â | Â | NCT03206177 | Combination with paclitaxel and carboplatin | Ovarian carcinosarcoma (25) | I |
Vactosertib | TGF-β receptor | NCT03724851 | Combination with pembrolizumab | Gastrointestinal cancers (67) | I/II |
| Â | Â | NCT03732274 | Combination with durvalumab | Metastatic non-small-cell lung cancer (63) | I/II |
| Â | Â | NCT03698825 | Combination with paclitaxel | Metastatic gastric cancer (62) | I/II |
| Â | Â | NCT04064190 | Combination with durvalumab | Urothelial carcinoma (48) | I/II |
| Â | Â | NCT04515979 | Combination with pembrolizumab | Non-small-cell lung cancer (55) | II |
| Â | Â | Â | Combination with nal-IRI/FL | Pancreas cancer (28) | I |
LY3200882 | TGF-β receptor | NCT02937272 | Monotherapy | Malignant solid tumours (223) | I |
NIS793 | TGF-β | NCT02947165 | Combination with PDR001 | Malignant solid tumours (120) | I |
AVID200 | TGF-β | NCT03834662 | Monotherapy | Malignant solid tumours (19) | I |
TPX-0022 | MET, CSF-1R and SRC | NCT03993873 | Monotherapy | Advanced-stage solid tumours (120) | I |
IMC-CS4 | CSF1R | NCT03153410 | Combination with cyclophosphamide, GVAX and pembrolizumab | Pancreatic cancer (12) | I |
MCS110 | CSF-1 | NCT03694977 | Combination with PDR001 | Gastric cancer (30) | II |
Chiauranib | Aurora B, VEGFR, PDGFR, KIT and CSF-1R | NCT03216343 | Monotherapy | Small-cell lung cancer (27) | I |
Cabiralizumab | CSF-1R | NCT03502330 | Combination with APX005M and nivolumab | Advanced-stage melanoma, non-small-cell lung cancer or renal cell carcinoma (120) | I |
BLZ945 | CSF-1R | NCT02829723 | Combination with PDR001 | Advanced-stage solid tumours (200) | I/II |
DCC-3014 | CSF-1R | NCT03069469 | Monotherapy | Tenosynovial giant cell tumour (120) | I/II |
| Â | CSF-1R | NCT04242238 | Combination with avelumab | Advanced-stage arcomas (48) | I |
NMS-03592088 | FLT3, KIT and CSF-1R | NCT03922100 | Monotherapy | Acute myeloid leukaemia or chronic myelomonocytic leukaemia (140) | I/II |
Chiauranib | Aurora B, VEGFR, PDGFR, KIT and CSF-1R | NCT03245190 | Monotherapy | Hepatocellular carcinoma (35) | I |
BMS-813160 | CCR2/5 | NCT04123379 | Combination with nivolumab | Non-small-cell lung cancer or hepatocellular carcinoma (50) | II |
| Â | Â | NCT03767582 | Combination with nivolumab and GVAX | Pancreatic ductal adenocarcinoma (30) | I/II |
| Â | Â | NCT02996110 | Combination with nivolumab | Advanced-stage renal cell carcinoma (200) | II |
| Â | Â | NCT03496662 | Combination with nivolumab, gemcitabine and paclitaxel | Pancreatic ductal adenocarcinoma (53) | I/II |
Leronlimab | CCR5 | NCT04504942 | Monotherapy | Advanced-stage solid tumours (30) | II |
| Â | Â | NCT03838367 | Combination with carboplatin | Triple-negative breast neoplasms (48) | I/II |
SX-682 | CXCR1/2 | NCT03161431 | Combination with pembrolizumab | Metastatic melanoma (77) | I |
AZD5069 | CXCR2 | NCT03177187 | Combination with enzalutamide | Metastatic castration-resistant prostate cancer (49) | I/II |
Plerixafor | CXCR4 | NCT02605460 | Combination with busulfan and cyclophosphamide | Acute myeloid leukaemia or acute lymphoid leukaemia (20) | II |
BL-8040 | CXCR4 | NCT02763384 | Combination with nelarabine | T cell acute lymphoblastic leukaemia (20) | II |
IPH5401 | C5aR | NCT03665129 | Combination with durvalumab | Advanced-stage solid tumours (140) | I |